<DOC>
	<DOCNO>NCT01593761</DOCNO>
	<brief_summary>Primary Objective : To make preliminary assessment efficacy CG400549 ( 960 mg daily ) subject cABSSSI ( major cutaneous abscess ) due MRSA . Secondary Objective ( ) : - To assess pharmacokinetics CG400549 ( 960 mg daily ) subject cABSSSI due MRSA - To explore vitro susceptibility cABSSSI-related bacteria CG400549 . - To assess safety multiple dos CG400459</brief_summary>
	<brief_title>Phase 2a Study CG400549 Treatment cABSSSI Caused Methicillin-resistant Staphylococcus Aureus</brief_title>
	<detailed_description>This open-label , exploratory study evaluate safety , pharmacokinetics , efficacy CG400549 , daily 10 14 day , subject cABSSSI ( major cutaneous abscess ) due MRSA . All subject receive active treatment . Subjects begin study treatment upon confirmation clinical eligibility ( ie , confirmation MRSA infection require pretreatment ) . Subjects begin treatment CG400549 subsequently find S. aureus infection discontinue study treatment , treat appropriate identify pathogen ( ) , follow safety . These subject include safety analysis primary efficacy analysis .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Staphylococcal Infections</mesh_term>
	<mesh_term>Skin Diseases , Infectious</mesh_term>
	<mesh_term>Methicillin</mesh_term>
	<criteria>1 . Diagnosis major cutaneous abscess suspect confirm caused MRSA . 2 . Signs symptom include least 2 follow : purulent drainage discharge , erythema , fluctuance , heat localize warmth , edema/induration , pain tenderness palpation 1 . Prior systemic topical antibacterial therapy 2 . Severe sepsis refractory shock</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>cABSSSI</keyword>
	<keyword>MRSA</keyword>
</DOC>